• Biophysical Insights into Lipid Nanoparticle Structure for m

  2026-04-29

  This article reviews a recent study that applies advanced solution-based biophysical techniques to elucidate the structural and functional heterogeneity of lipid nanoparticles (LNPs) used for mRNA delivery. The findings provide a granular understanding of LNP polydispersity, RNA loading, and structure–function relationships, with implications for optimizing gene delivery systems and translation efficiency.

• CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal Stu

  2026-04-28

  CA-074 Me is a potent, cell-permeable cathepsin B inhibitor used for dissecting lysosomal enzyme functions and regulated cell death. Its selectivity and solubility profile make it a gold standard in apoptosis assay and inflammation research. APExBIO supplies CA-074 Me (SKU A8239) to support reproducible, high-sensitivity workflows.

• NFE2L1-DDI2-Proteasome Axis Protects Cells from RSL3-Induced

  2026-04-28

  This study elucidates how activation of the NFE2L1-ubiquitin-proteasome system via DDI2 confers cellular protection against ferroptosis, particularly in the context of GPX4 inhibition by RSL3. The findings highlight critical adaptive mechanisms within the ubiquitin-proteasome system that modulate ferroptotic cell death, revealing new molecular targets for enhancing ferroptosis-based cancer therapies.

• Partial BACE1 Inhibition Preserves Synaptic Transmission in

  2026-04-27

  Satir et al. (2020) demonstrate that moderate BACE1 inhibition, reducing amyloid beta (Aβ) production by up to 50%, does not impair synaptic transmission in primary neuronal cultures. These findings refine the safety profile of BACE inhibitors such as LY2886721 and inform dose strategies for Alzheimer's disease research.

• EGCG Nanoparticles Enhance FLASH-RT Antitumor Efficacy via R

  2026-04-27

  This study demonstrates that functionalized self-assembled EGCG nanoparticles (BENPs) can significantly boost the antitumor effects of ultra-high dose rate radiotherapy (FLASH-RT) by promoting reactive oxygen species (ROS) generation and modulating the immune microenvironment. The findings suggest a promising strategy for optimizing FLASH-RT efficacy while maintaining favorable biosafety profiles.

• Veratridine: Voltage-Gated Sodium Channel Opener for Researc

  2026-04-26

  Veratridine is a potent voltage-gated sodium channel opener used in neuroscience and cancer research. It enables precise study of sodium channel dynamics, excitotoxicity, and screening of sodium channel blockers. APExBIO's Veratridine (B7219) offers validated performance and reproducibility.

• Extracellular RNA-Protein Complexes in Arabidopsis Apoplast

  2026-04-25

  This study challenges the prevailing model that small RNAs in Arabidopsis apoplastic fluid are primarily encapsulated in extracellular vesicles. Instead, it demonstrates that both small RNAs and circular long noncoding RNAs associate with proteins outside vesicles, revealing new mechanisms for RNA stability and secretion.

• Perphenazine: Dopamine D2 Receptor Antagonist for Research W

  2026-04-24

  Perphenazine (SKU B6157) from APExBIO delivers reliable, reproducible results for neuropharmacology and immunomodulation research. Its robust dopamine D2 receptor antagonist profile and validated mechanisms—ranging from mitochondria-mediated cell death to host-directed antibacterial effects—enable advanced experimental design and troubleshooting.

• Topotecan's Mechanism and Clinical Impact: Lessons for DNA D

  2026-04-24

  This review of Kollmannsberger et al. (1999) details the pharmacology and clinical development of topotecan, a topoisomerase I inhibitor with a distinctive mechanism inducing DNA strand breaks and apoptosis. The paper's insights into topotecan's activity, pharmacokinetics, and integration into combination regimens inform both experimental design and translational cancer research.

• Elobixibat Hydrate: Mechanistic Insights and Translational I

  2026-04-23

  Explore the advanced mechanism of Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, with a focus on translational implications in chronic idiopathic constipation and metabolic disease. This article delivers new mechanistic clarity, practical assay guidance, and a unique cross-domain perspective.

• Mechanistic Mastery: Lysis Buffer’s Role in Translational Ge

  2026-04-23

  This thought-leadership article unpacks the mechanistic and strategic significance of specialized lysis buffers—specifically as components of rapid genotyping kits for mouse tail tissue—in advancing translational research. By connecting protocol optimization, competitive benchmarking, and the downstream impact on biomarker discovery and clinical translation, researchers are equipped with actionable guidance to bridge preclinical insight and clinical innovation. The article directly references Bai et al. (2026), leveraging their findings on autophagy–metastasis signatures in colorectal cancer to illustrate the broader translational relevance. Contextual internal links and detailed protocol parameters support credible, evidence-based guidance.

• Redefining mRNA Reporter Assays: Mechanistic and Strategic I

  2026-04-22

  This article provides a thought-leadership perspective on the strategic selection and mechanistic underpinnings of advanced Firefly Luciferase mRNA reporters for translational research. We dissect the molecular rationale for 5-moUTP modifications, benchmark the competitive landscape, and synthesize guidance for researchers aiming to optimize mRNA delivery and translation efficiency assays. Drawing on recent advances in cancer vaccine delivery systems and integrating key findings from Yufei Xia's thesis, we position EZ Cap™ Firefly Luciferase mRNA (5-moUTP) as a gold standard for robust, reproducible, and low-immunogenicity reporter gene studies.

• Bromodomain Inhibitor, (+)-JQ1: Protocols, Workflows & Troub

  2026-04-22

  Bromodomain Inhibitor, (+)-JQ1 offers precise BET targeting for advanced apoptosis, ferroptosis, inflammation, and male contraception research. This guide translates recent breakthroughs and troubleshooting tactics into actionable workflows, maximizing reproducibility and data impact with APExBIO’s trusted reagent.

• Dual-Action Inhibition of p38α MAPK: Conformational Control

  2026-04-21

  The study elucidates how certain kinase inhibitors not only block p38α MAPK activity but also accelerate its dephosphorylation by stabilizing activation loop conformations accessible to phosphatases. This dual-action mechanism has significant implications for the design of highly specific kinase inhibitors with improved therapeutic profiles.

• L-NMMA Acetate: Precision NOS Pathway Modulation in Research

  2026-04-21

  L-NMMA acetate (N(G)-monomethyl-L-arginine acetate) from APExBIO empowers translational researchers to dissect and manipulate nitric oxide signaling with unmatched specificity. This guide delivers actionable experimental workflows, advanced use-cases, and troubleshooting insights for maximizing reproducibility and innovation in nitric oxide pathway studies.

407 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page